|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Fixed maturities, available for sale, at fair value (amortized cost $97,423 and $91,717; allowance for expected credit losses of $2 and $3) | ||||||||||||||||||||
| Equity securities, at fair value (cost $414 and $457) | ||||||||||||||||||||
| Real estate investments | ||||||||||||||||||||
| Short-term securities | ||||||||||||||||||||
| Other investments | ||||||||||||||||||||
| Total investments | ||||||||||||||||||||
| Cash (including restricted cash of $147 and $132) | ||||||||||||||||||||
| Investment income accrued | ||||||||||||||||||||
| Premiums receivable (net of allowance for expected credit losses of $69 and $58) | ||||||||||||||||||||
| Reinsurance recoverables (net of allowance for estimated uncollectible reinsurance of $142 and $129) | ||||||||||||||||||||
| Ceded unearned premiums | ||||||||||||||||||||
| Deferred acquisition costs | ||||||||||||||||||||
| Deferred taxes | ||||||||||||||||||||
| Contractholder receivables (net of allowance for expected credit losses of $13 and $16) | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Other intangible assets | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Assets held for sale | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities | ||||||||||||||||||||
| Claims and claim adjustment expense reserves | ||||||||||||||||||||
| Unearned premium reserves | ||||||||||||||||||||
| Contractholder payables | ||||||||||||||||||||
| Payables for reinsurance premiums | ||||||||||||||||||||
| Debt | ||||||||||||||||||||
| Other liabilities | ||||||||||||||||||||
| Liabilities held for sale | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Shareholders’ equity | ||||||||||||||||||||
| Common stock (1,750.0 shares authorized; 204.9 and 217.5 shares issued and outstanding) | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||||||||
| Treasury stock, at cost (561.0 and 559.2 shares) | ||||||||||||||||||||
| Treasury stock, at cost (590.8 and 575.9 shares) | ||||||||||||||||||||
| Total shareholders’ equity | ||||||||||||||||||||
| Total liabilities and shareholders’ equity | ||||||||||||||||||||
Loading...
